{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000029","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.617727+00:00","generated_at":"2026-06-05T07:13:44.656291+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GoodRx Q4 revenue $196.6M; net loss $25.9M; adj. EBITDA $57.3M","bullets":["Q4 2023 revenue $196.6M, net loss $25.9M (13.2% margin), adjusted net income $31.1M (15.8% margin).","Full year 2023 revenue $750.3M, net loss $8.9M, adjusted EBITDA $217.4M (28.6% margin).","Q4 net cash from operations $15.9M; exited with over 7M consumers of prescription offerings.","Interim CEO Scott Wagner expects continued topline growth in Q1 and full year 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000029","json":"https://secwatch.observer/filing/0001809519-24-000029.json","markdown":"https://secwatch.observer/filing/0001809519-24-000029.md","text":"https://secwatch.observer/filing/0001809519-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/0001809519-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/gdrx-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:13:44.656291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7096ccdf3485c3f0303b182112a235829d5a269","claim":"GoodRx Holdings, Inc. reported financial results for the three months and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three months and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/0001809519-24-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}